DSM scales up pharma business with $2.6 bln private equity deal

DSM has agreed a $2.6 billion joint venture deal with U.S. private equity firm JLL to give its pharmaceuticals division enough scale to expand into new markets as the Dutch group shifts towards higher-margin products.